YD Bio (NASDAQ:YDES) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of YD Bio (NASDAQ:YDES) to a hold rating in a research note released on Saturday,Wall Street Zen reports.

YD Bio Stock Up 24.1%

YDES stock opened at $7.11 on Friday. The company has a fifty day moving average price of $3.42 and a two-hundred day moving average price of $4.16. YD Bio has a one year low of $1.70 and a one year high of $22.00.

YD Bio (NASDAQ:YDES) last released its quarterly earnings data on Tuesday, September 1st. The biotechnology company reported $0.05 EPS for the quarter. The company had revenue of $0.42 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its position in YD Bio stock. Cypress Capital Management LLC WY grew its stake in shares of YD Bio Limited (NASDAQ:YDES) by 9.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,690 shares of the biotechnology company’s stock after acquiring an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 at the end of the most recent quarter.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.